Exelixis, Inc. (EXEL) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript

Michael Schmidt
Guggenheim Securities, LLC, Research Division

Welcome to this next fireside chat with Exelixis. With us today, we have Mike Morrissey, President and CEO. Mike, welcome. Thanks for joining us again.

Michael Morrissey
CEO, President & Director

Great to be here, Michael. Thanks for the invite. Before we begin, I’ll be making forward-looking statements. So please see our SEC filings for a description of the risks that we face in our business.

Michael Schmidt
Guggenheim Securities, LLC, Research Division

Sounds good. Great. Thank you, Mike. So Mike, there are a lot of moving parts at Exelixis. You have the commercial story with CABOMETYX. You have recent and upcoming data card flips for zanzalintinib, your key pipeline product, and you have an evolving early-stage pipeline. And so before we jump into Q&A, could you just provide us with a quick introduction and contextualize where Exelixis stands as a company today?

Michael Morrissey
CEO, President & Director

I’d be happy to. Thank you. Good morning. Good to see you again. Great to be here, kind of a rainy day in Boston. So I’ll hopefully provide some illumination. Yes. So let’s talk about Exelixis. Let’s talk about earnings that we had last week, kind of set the stage for all the other topics and where we’re going as we close out ’25 heading into ’26.

We’re a midsized commercial stage biotech company focused exclusively in oncology. We have kind of ridden the roller coaster of ups and downs over the last 25 years, the last 10 years in terms of how we’ve been able to navigate